Clinical Trials · NCT04914195

Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer

Name: Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Gonadorelin

Phase: Phase 3
Recruitment status: Completed
Sponsor: Bharat Serums and Vaccines Limited
Enrollment: 155
Start date: Jul 2021
Locations: 2 sites, India
Primary endpoint: Testosterone response rate defined as Testosterone values sustained below castration level (0.5 ng/mL or 50 ng/dL) i.e. all Testosterone values at and after Day 28 until Day 57 must be < 0.5 ng/mL or < 50 ng/dL

View Gonadorelin compound reference